Abstract:Vitiligo is an acquired chronic depigmenting disorder of the skin, with an estimated prevalence of 0.5% of the general population, characterized by the development of white macules resulting from a loss of epidermal melanocytes. The nomenclature has been revised after an extensive international work within the vitiligo global issues consensus conference, and vitiligo (formerly non-segmental vitiligo) is now a consensus umbrella term for all forms of generalized vitiligo. Two other subsets of vitiligo are segmental vitiligo and unclassified/undetermined vitiligo, which corresponds to focal disease and rare variants. A series of hypopigmented disorders may masquerade as vitiligo, and some of them need to be ruled out by specific procedures including a skin biopsy. Multiple mechanisms are involved in melanocyte disappearance, namely genetic predisposition, environmental triggers, metabolic abnormalities, impaired renewal, and altered inflammatory and immune responses. The auto-immune/inflammatory theory is the leading hypothesis because (1) vitiligo is often associated with autoimmune diseases; (2) most vitiligo susceptibility loci identified through genome-wide association studies encode immunomodulatory proteins; and (3) prominent immune cell infiltrates are found in the perilesional margin of actively depigmenting skin. However, other studies support melanocyte intrinsic abnormalities with poor adaptation of melanocytes to stressors leading to melanocyte instability in the basal layer, and release of danger signals important for the activation of the immune system. Recent progress in the understanding of immune pathomechanisms opens interesting perspectives for innovative treatment strategies. The proof of concept in humans of targeting of the IFNγ /Th1 pathway is much awaited. The interplay between oxidative stress and altered immune responses suggests that additional strategies aiming at limiting type I interferon activation pathway as background stabilizing therapies could be an interesting approach in vitiligo. This review covers classification and clinical aspects, pathophysiology with emphasis on immunopathogenesis, and promising therapeutic approaches.

Role of Cytokines and Chemokines in Vitiligo and Their Therapeutic Implications

Role of Cytokines in Vitiligo: Pathogenesis and Possible Targets for Old and New Treatments

Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy

Vitiligo: A focus on pathogenesis and its therapeutic implications

Clinical Features, Immunopathogenesis, and Therapeutic Strategies in Vitiligo

Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention

The Promising Role of Chemokines in Vitiligo: From Oxidative Stress to the Autoimmune Response

Vitiligo: Mechanisms of Pathogenesis and Treatment

Oxidative Stress and Potential Antioxidant Therapies in Vitiligo: A Narrative Review

Vitiligo: advances in pathophysiology research and treatment development

Autoimmunity in vitiligo: Therapeutic implications and opportunities

Roles of cytokines in the pathogenesis of vitiligo

Vitiligo: From Pathogenesis to Treatment

Vitiligo: Translational research and effective therapeutic strategies

Advances in vitiligo: Update on therapeutic targets

Current Concepts of Vitiligo Immunopathogenesis

Polyphenols targeting multiple molecular targets and pathways for the treatment of vitiligo

Treatment update for vitiligo based on autoimmune inhibition and melanocyte protection

An update on Vitiligo pathogenesis

Up-and-Coming Drugs for the Treatment of Vitiligo

The enigma and challenges of vitiligo pathophysiology and treatment